Vertex Pharmaceuticals Presents New Data From Phase 1/2 Clinical Trial Of VX-880 Stem Cell-Derived Islet Cell Therapy For Type 1 Diabetes; Updated Results On 12 Patients Show Consistency With Previous Findings And Highlight Transformative Potential

Author: Benzinga Newsdesk | June 21, 2024 03:46pm

– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 –

– All patients achieved ADA-recommended target HbA1c levels <7.0% and >70% time-in-range (70-180 mg/dL), and 11 of 12 patients reduced or eliminated use of exogenous insulin –

- 3 patients with at least 12 months of follow-up, and therefore evaluable, met the primary endpoint of elimination of severe hypoglycemic events (SHEs) with HbA1c <7.0%, and the secondary endpoint of insulin independence –

- Trial expanded to enroll ~37 participants as company progresses toward pivotal development –

Posted In: VRTX